Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al.
Translational Andrology and Urology (2021) Vol. 10, Iss. 3, pp. 1506-1520
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Epidemiology and Prevention of Renal Cell Carcinoma
Tomoyuki Makino, Suguru Kadomoto, Kouji Izumi, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 4059-4059
Open Access | Times Cited: 76
WHO 2022 landscape of papillary and chromophobe renal cell carcinoma
João Lobo, Riuko Ohashi, Mahul B. Amin, et al.
Histopathology (2022) Vol. 81, Iss. 4, pp. 426-438
Closed Access | Times Cited: 70
The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges
Sambit K. Mohanty, Anandi Lobo, Liang Cheng
Human Pathology (2022) Vol. 136, pp. 123-143
Closed Access | Times Cited: 46
Effect of smoking, hypertension and lifestyle factors on kidney cancer — perspectives for prevention and screening programmes
Riccardo Campi, Giacomo Rebez, Tobias Klatte, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 11, pp. 669-681
Closed Access | Times Cited: 36
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers
Daniela Perotti, Maureen J. O’Sullivan, Amy L. Walz, et al.
Nature Reviews Urology (2025)
Closed Access | Times Cited: 1
Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence
Anna Julie Peired, Riccardo Campi, Maria Lucia Angelotti, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4588-4588
Open Access | Times Cited: 52
Papillary renal cell carcinoma: current and controversial issues
Silvia Angori, João Lobo, Holger Moch
Current Opinion in Urology (2022) Vol. 32, Iss. 4, pp. 344-351
Open Access | Times Cited: 28
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
Giovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3995-3995
Open Access | Times Cited: 24
A review of neoplasms with MITF/MiT family translocations.
Shuanzeng Wei, Joseph R. Testa, Pedram Argani
PubMed (2022) Vol. 37, Iss. 4, pp. 311-321
Closed Access | Times Cited: 23
Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel–Lindau-Disease-Associated Tumors
Cristina Suárez, María Vieito, Augusto Valdivia, et al.
Medical Sciences (2023) Vol. 11, Iss. 3, pp. 46-46
Open Access | Times Cited: 13
Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis
Mahul B. Amin, Jesse K. McKenney, Guido Martignoni, et al.
Modern Pathology (2022) Vol. 35, Iss. 10, pp. 1306-1316
Closed Access | Times Cited: 20
Varieties of altered TFE3 can occur in MiT-family-related renal cell carcinomas
Ann R. Kennedy, Hassan D. Kanaan, Kanika Arora, et al.
International Urology and Nephrology (2025)
Closed Access
Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics
Daniel D. Shapiro, Marı́a Virumbrales-Muñoz, David J. Beebe, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma
Alessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 307-307
Open Access | Times Cited: 3
The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth
João Lobo, Riuko Ohashi, Birgit Helmchen, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1418-1418
Open Access | Times Cited: 21
Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study
João Lobo, Markus Rechsteiner, Birgit Helmchen, et al.
Histopathology (2022) Vol. 81, Iss. 1, pp. 32-43
Closed Access | Times Cited: 14
Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives
Alfredo Distante, Laura Marandino, Riccardo Bertolo, et al.
Diagnostics (2023) Vol. 13, Iss. 13, pp. 2294-2294
Open Access | Times Cited: 8
Acquired cystic disease associated renal cell carcinoma: A clinicopathologic and molecular study of 31 tumors
Ejas Palathingal Bava, Joseph Sanfrancesco, Ahmed Alkashash, et al.
Human Pathology (2024) Vol. 149, pp. 48-54
Closed Access | Times Cited: 2
Succinate Dehydrogenase Defects Giant Renal Cell Carcinoma
Xia Sun, Guang Wang, Ziye Huang, et al.
Urologia Internationalis (2023) Vol. 107, Iss. 8, pp. 819-822
Open Access | Times Cited: 4
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now
Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al.
Translational Andrology and Urology (2021) Vol. 10, Iss. 3, pp. 1499-1505
Open Access | Times Cited: 8
Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort
Si Hyun Kim, Jang Hee Han, Seung‐hwan Jeong, et al.
BMC Urology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives
Alfredo Distante, Laura Marandino, Riccardo Bertolo, et al.
(2023)
Open Access | Times Cited: 3
Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
Viktor Grünwald, Lothar Bergmann, Bernhard Brehmer, et al.
World Journal of Urology (2022) Vol. 40, Iss. 10, pp. 2381-2386
Open Access | Times Cited: 5
Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
Eun-mi Yu, Mythri Mudireddy, Ishan Patel, et al.
Uro (2023) Vol. 3, Iss. 2, pp. 117-131
Open Access | Times Cited: 2
Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
Laura Pohl, Jana Friedhoff, Christina Jurcic, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top